ATE257160T1 - Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde - Google Patents

Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde

Info

Publication number
ATE257160T1
ATE257160T1 AT98944070T AT98944070T ATE257160T1 AT E257160 T1 ATE257160 T1 AT E257160T1 AT 98944070 T AT98944070 T AT 98944070T AT 98944070 T AT98944070 T AT 98944070T AT E257160 T1 ATE257160 T1 AT E257160T1
Authority
AT
Austria
Prior art keywords
proteins
hinge regions
medicine
peptide sequences
immunoglobulin fragments
Prior art date
Application number
AT98944070T
Other languages
English (en)
Inventor
David Paul Humphreys
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of ATE257160T1 publication Critical patent/ATE257160T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98944070T 1997-09-19 1998-09-21 Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde ATE257160T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9720054.7A GB9720054D0 (en) 1997-09-19 1997-09-19 Biological products
PCT/GB1998/002851 WO1999015549A2 (en) 1997-09-19 1998-09-21 Peptide sequences as hinge regions in proteins like immunoglobulin fragments and their use in medicine

Publications (1)

Publication Number Publication Date
ATE257160T1 true ATE257160T1 (de) 2004-01-15

Family

ID=10819407

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98944070T ATE257160T1 (de) 1997-09-19 1998-09-21 Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde

Country Status (9)

Country Link
US (1) US6642356B1 (de)
EP (1) EP1015495B1 (de)
JP (1) JP4257030B2 (de)
AT (1) ATE257160T1 (de)
AU (1) AU9174398A (de)
DE (1) DE69820885T2 (de)
ES (1) ES2212340T3 (de)
GB (1) GB9720054D0 (de)
WO (1) WO1999015549A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
DE60224822T2 (de) * 2001-10-19 2009-01-22 Zymogenetics, Inc., Seattle Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
EP1687026B1 (de) 2003-11-21 2008-05-14 UCB Pharma, S.A. Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
US7381794B2 (en) * 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
CA2593212A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
ES2382879T3 (es) 2005-09-14 2012-06-14 Ucb Pharma, S.A. Conjugado de anticuerpo - polímero de peine.
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
EA019636B1 (ru) 2007-03-22 2014-05-30 Байоджен Айдек Ма Инк. Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
EP2195341B1 (de) 2007-09-26 2017-03-22 UCB Biopharma SPRL Fusionsantikörper mit dualer spezifität
EP2475682B1 (de) 2009-09-10 2018-01-31 UCB Biopharma SPRL Polyvalente antikörper
GB0916630D0 (en) 2009-09-22 2009-11-04 Secr Defence Antibody
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
EP2565667A1 (de) 2011-08-31 2013-03-06 Friedrich-Alexander-Universität Erlangen-Nürnberg Ankunftsrichtungsschätzung mittels mit einem Wasserzeichen versehenen Audiosignalen und Mikrofonanordnungen
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
EP2776466B1 (de) 2011-11-11 2017-08-23 UCB Biopharma SPRL Albuminbindende antikörper und bindungsfragmenten davon
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
UY36021A (es) 2014-03-05 2015-09-30 Ucb Biopharma Sprl Proteìnas fc multimèricas
WO2016189045A1 (en) 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
DK3723791T3 (da) 2017-12-14 2024-04-08 CSL Behring Lengnau AG Rekombinante igg-fc-multimere til behandling af neuromyelitis optica
GB201804243D0 (en) * 2018-03-16 2018-05-02 Liverpool School Tropical Medicine Hinge sequences
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
WO2020236795A2 (en) 2019-05-21 2020-11-26 Novartis Ag Trispecific binding molecules against bcma and uses thereof
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
CN114585651A (zh) 2019-08-08 2022-06-03 再生元制药公司 新型抗原结合分子形式
US20220332847A1 (en) 2019-09-13 2022-10-20 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS
BR112022008552A2 (pt) 2019-11-05 2022-08-09 Regeneron Pharma Moléculas de ligação multiespecíficas de scfv de terminal-n
EP4077397A2 (de) 2019-12-20 2022-10-26 Regeneron Pharmaceuticals, Inc. Neuartige il-2-agonisten und verfahren zur verwendung davon
EP4126241A1 (de) 2020-03-27 2023-02-08 Novartis AG Bispezifische kombinationstherapie zur behandlung proliferativer erkrankungen und autoimmunerkrankungen
WO2021231447A1 (en) 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Novel il10 agonists and methods of use thereof
KR20230086765A (ko) 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
EP4240494A1 (de) 2020-11-06 2023-09-13 Novartis AG Anti-cd19-mittel und auf b-zellen abzielende kombinationstherapie zur behandlung von b-zell-malignomen
MX2023012974A (es) 2021-05-04 2023-11-15 Regeneron Pharma Agonistas multiespecificos de receptores del fgf21 y sus usos.
WO2023004282A2 (en) 2021-07-19 2023-01-26 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
AU2022331241A1 (en) 2021-08-16 2024-03-28 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
CA3238029A1 (en) 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
WO2023220647A1 (en) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
US20230382969A1 (en) 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2023235848A1 (en) 2022-06-04 2023-12-07 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024130175A2 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses
WO2024138191A1 (en) 2022-12-23 2024-06-27 Regeneron Pharmaceuticals, Inc. Ace2 fusion proteins and uses thereof
US20240247069A1 (en) 2023-01-13 2024-07-25 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2024151978A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2024182451A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. Multivalent anti-spike protein binding molecules and uses thereof
WO2024182540A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. T cell activators and methods of use thereof
WO2024182455A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. Multivalent anti-spike protein binding molecules and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284898A3 (de) 1987-04-02 1990-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Hinge-Peptid, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung synthetischer Immunogene
DE69332377T2 (de) * 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide

Also Published As

Publication number Publication date
AU9174398A (en) 1999-04-12
US6642356B1 (en) 2003-11-04
DE69820885D1 (de) 2004-02-05
EP1015495B1 (de) 2004-01-02
EP1015495A2 (de) 2000-07-05
GB9720054D0 (en) 1997-11-19
WO1999015549A3 (en) 1999-06-17
JP4257030B2 (ja) 2009-04-22
ES2212340T3 (es) 2004-07-16
WO1999015549A2 (en) 1999-04-01
JP2001517423A (ja) 2001-10-09
DE69820885T2 (de) 2004-12-16

Similar Documents

Publication Publication Date Title
ATE257160T1 (de) Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde
Aggarwal et al. Human tumor necrosis factor. Production, purification, and characterization.
Selsted et al. Determination of the disulfide array in the human defensin HNP-2: a covalently cyclized peptide
Hackeng et al. Total chemical synthesis of human matrix Gla protein
Wilkinson Troponin C from rabbit slow skeletal and cardiac muscle is the product of a single gene
Mann et al. Solubilization of protein BM‐40 from a basement membrane tumor with cheating agents and evidence for its identity with osteonectin and SPARC
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
ES2147558T3 (es) Nuevos polipeptidos para promover la fijacion celular.
NO20005612L (no) Bindingsmolekyler avledet fra immunoglobuliner som ikke trigger komplementformidlet lysis
NZ336929A (en) Purified receptor that binds TRAIL and antibodies thereof
DE69129803D1 (de) Wasserlösliche peptidanaloguen mit bindungstellen
GB9722320D0 (en) Human cell cycle checkpoint proteins
AggarwalS et al. Human tumor necrosis factor
Milstein et al. Disulphide bridges of the heavy chain of human immunoglobulin G2
Araki et al. The position of the disulfide bonds in human plasma α2HS-glycoprotein and the repeating double disulfide bonds in the domain structure
DE69925116D1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
DE69832299D1 (de) Einkettigen polypeptiden enthalten troponin i und troponin c
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
Garcia-Pardo et al. Primary structure of human plasma fibronectin—characterization of the 6,000 dalton C-terminal fragment containing the interchain disulfide bridges
WO2000049038A3 (de) Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
Le-Nguyen et al. Design and chemical synthesis of a 32 residues chimeric microprotein inhibiting both trypsin and carboxypeptidase A
Pomroy et al. Conjugation of polyethylene glycol via a disulfide bond confers water solubility upon a peptide model of a protein transmembrane segment
DE69533545D1 (de) Faltende proteine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1015495

Country of ref document: EP

REN Ceased due to non-payment of the annual fee